CliffBio
biologic

Amjevita

adalimumab-atto

Loss of exclusivity—loss of exclusivity
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameAmjevita
Active ingredientadalimumab-atto
Strength10MG/0.2ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalApril 2023
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Amjevita patent cliff — loss of exclusivity — | CliffBio